Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
4.850
-0.150 (-3.00%)
At close: Mar 11, 2026, 4:00 PM EDT
4.976
+0.126 (2.60%)
After-hours: Mar 11, 2026, 7:10 PM EDT
Voyager Therapeutics Employees
Voyager Therapeutics had 172 employees as of December 31, 2024. The number of employees increased by 10 or 6.17% compared to the previous year.
Employees
172
Change (1Y)
10
Growth (1Y)
6.17%
Revenue / Employee
$234,733
Profits / Employee
-$696,052
Market Cap
289.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 172 | 10 | 6.17% | 172 | 0 |
| Dec 31, 2023 | 162 | 37 | 29.60% | 162 | 0 |
| Dec 31, 2022 | 125 | 24 | 23.76% | 125 | 0 |
| Dec 31, 2021 | 101 | -78 | -43.58% | 101 | 0 |
| Dec 31, 2020 | 179 | -7 | -3.76% | 177 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Editas Medicine | 246 |
| Humacyte | 220 |
| Protalix BioTherapeutics | 213 |
| MediWound | 111 |
| Keros Therapeutics | 78 |
| Cartesian Therapeutics | 66 |
| Sol-Gel Technologies | 34 |
| Eledon Pharmaceuticals | 31 |
VYGR News
- 2 days ago - Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - GlobeNewsWire
- 8 days ago - Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 4 weeks ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia - GlobeNewsWire
- 4 months ago - Voyager Reports Third Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 6 months ago - Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 7 months ago - Voyager Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 8 months ago - Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewsWire